Solid Organ Transplantation Recipient clinical trials at UCSF
1 in progress, 1 open to new patients
Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papillomavirus-Related Cancer in Adult Women After Kidney Transplant
open to eligible females ages 18–49
This phase II trial studies how well recombinant human papillomavirus nonavalent vaccine works in preventing human papillomavirus-related cancer in adult women after kidney transplant. Vaccines made from peptides of human papillomavirus may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer.
San Francisco, California and other locations